Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Technetium 99m-RHN 001 - Rhine Pharma

Next Previous
X
Search
Drug Profile

Technetium 99m-RHN 001 - Rhine Pharma

Alternative Names: 99mTc-RHN001; RHN001-Dx (99mTc-PSMA); technetium-99m (99mTc)

Latest Information Update: 20 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telix Pharmaceuticals; University Hospital Heidelberg
  • Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Radionuclide imaging enhancers; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Prostate cancer

Most Recent Events

  • 30 Oct 2024 Clinical trials in Prostate cancer (Diagnosis) (unspecified route) (Rhine Pharma website, October 2024)
  • 23 Oct 2024 Preclinical trials in Prostate cancer in Australia (unspecified route) prior to October 2024
  • 23 Oct 2024 South African Health Products Regulatory Authority (SAHPRA) approves trial application for Technetium 99m-RHN 001 in prostate cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top